UroGen Pharma (URGN) stock falls as the company faces a major setback after an FDA panel votes against its bladder cancer ...

Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...

Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease ...

The FDA ODAC decided that the overall benefit-risk of the investigational therapy UGN-102 is not favorable in patients with ...

Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of ...

Roger Li, MD, discusses the MoonRISe-1 study evaluating TAR-210 in FGFR-altered intermediate-risk non-muscle-invasive bladder cancer.

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...

Pharma giant AstraZeneca has reported positive results from a Phase III trial of its treatment for non-muscle-invasive ...

The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

In the POTOMAC study, one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance ...

The antibody has been approved for muscle-invasive bladder cancer (MIBC) in the US and other nations, based on the outcomes ...

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...